Table 1. Baseline characteristics.
| Variable | Total | LD (n=198) | ED (n=135) | p-value |
|---|---|---|---|---|
| Age, yr | 0.488 | |||
| ≤65 | 165 (49.5) | 95 (48.0) | 70 (51.9) | |
| >65 | 168 (50.5) | 103 (52.0) | 65 (48.1) | |
| BMI, kg/m2 | 0.767 | |||
| ≤23 | 162 (48.6) | 95 (48.0) | 67 (49.6) | |
| >23 | 171 (51.4) | 103 (52.0) | 68 (50.4) | |
| ECOG PS | <0.001 | |||
| 0, 1 | 239 (71.8) | 176 (88.9) | 63 (46.7) | |
| 2 | 94 (28.2) | 22 (11.1) | 72 (53.3) | |
| Smoking | 0.643 | |||
| Current or ex-smoker | 285 (86) | 168 (85) | 117 (87) | |
| Non-smoker | 48 (14) | 18 (13) | ||
| Smoking (PY) | 40.0 (30.0–50.0) | 40.0 (28.0–50.0) | 42.5 (30.0–50.0) | 0000.152 |
| Comorbidity | ||||
| DM | 55 (16.5) | 31 (15.7) | 24 (17.8) | 0000.609 |
| HF | 1 (0.3) | 1 (0.5) | 0 (0) | >0.999* |
| CRF | 0 (0) | 0 (0) | 0 (0) | |
| LC | 2 (0.6) | 1 (0.5) | 1 (0.7) | >0.999* |
| CVA | 8 (2.4) | 7 (3.5) | 1 (0.7) | 0.149* |
| Inactive TB | 32 (9.6) | 16 (8.1) | 16 (11.9) | 0.252 |
| First CTx regimen | <0.001 | |||
| EP | 257 (77.2) | 179 (90.4) | 78 (57.8) | |
| EC | 76 (22.8) | 19 (9.6) | 57 (42.2) | |
| The sum of cycles | 0.099 | |||
| 2–3 | 48 (14.4) | 22 (11.1) | 26 (19.3) | |
| ≥4 | 285 (85.6) | 176 (88.9) | 109 (80.7) | |
| Thoracic RT (CCRT) | 0.053 | |||
| Yes | 209 (62.8) | 177 (89.4) | 32 (23.7) | |
| PCI | 0.019 | |||
| Yes | 113 (33.9) | 77 (38.9) | 36 (26.7) | |
| Progression of disease | 0.022 | |||
| Progression | 56 (16.8) | 41 (20.7) | 15 (11.1) | |
| Non-progression | 277 (83.2) | 157 (79.3) | 120 (88.9) | |
| Cause of death | <0.001 | |||
| Progression | 137 (80.1) | 28 (52.8) | 109 (92.4) | |
| Else | 34 (9.9) | 25 (47.2) | 9 (7.6) |
Values are presented as number (%).
*Using Fisher exact test.
LD: limited disease; ED: extensive disease; BMI: body mass index; ECOG PS: Eastern Cooperative Oncology Group performance status; PY: pack years; DM: diabetes mellitus; HF: heart failure: CRF: chronic renal failure; LC: liver cirrhosis; CVA: cerebrovascular disease; TB: tuberculosis; CTx: chemotherapy; EP: etoposide-cisplatin; EC: etoposide-carboplatin; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; PCI: prophylactic cranial irradiation.